Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

• Status: Completed
• Trial end date: 2019-11-20
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie
• Treatments: Tilavonemab

Criteria

Inclusion Criteria:

• Subject completed Study C2N-8E12-WW-104 (NCT02494024)

• Subject was not eligible to enroll in Study M15-562 (NCT02985879)

Exclusion Criteria:

• Subject weighs less than 35 kg at screening

• Subject has any contraindication or inability to tolerate brain MRI

• Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results